AtriCure (ATRC) CSO granted stock, transfers shares to cover taxes

Rhea-AI Filing Summary

AtriCure, Inc. Chief Scientific Officer Doraiswamy Vinayak reported equity awards and related tax withholding transactions in company common stock. He acquired 30,390 shares through a restricted stock award under the 2023 Stock Incentive Plan, with one third vesting on each of the first, second, and third anniversaries of the grant date. He also acquired 15,198 shares from the vesting and release of a performance share award after company performance goals and service requirements were met. To cover tax obligations from earlier restricted or performance share vesting, he transferred 15,585 shares back to AtriCure at a price of $31.26 per share.

Insider Trade Summary

3 transactions reported

Mixed 3 txns

Insider Doraiswamy Vinayak

Role Chief Scientific Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	30,390	$0.00	--
Grant/Award	Common Stock	15,198	$0.00	--
Tax Withholding	Common Stock	15,585	$31.26	$487K

Holdings After Transaction: Common Stock — 102,262 shares (Direct)

Footnotes (1)

1. The Reporting Person acquired these shares pursuant to a Restricted Stock Award under the AtriCure, Inc. 2023 Stock Incentive Plan. One third of the shares will vest annually upon the respective one, two, and three year anniversaries of the date of grant. The Reporting Person acquired these shares pursuant to the vesting and release of a Performance Share Award under the AtriCure, Inc. 2023 Stock Incentive Plan. The award had Company performance goals and a service period requirement which were met. The Reporting Person has elected to transfer these shares to the Company to satisfy the tax withholding obligation incurred upon the vesting and release of shares previously acquired pursuant to a Restricted Stock Award or Performance Share Award.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Doraiswamy Vinayak

(Last) (First) (Middle)

7555 INNOVATION WAY

(Street)

MASON OH 45040-9695

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
AtriCure, Inc. [ ATRC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/01/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/01/2026		A		30,390	A	$0(1)	102,262	D
Common Stock	03/01/2026		A		15,198	A	$0(2)	117,460	D
Common Stock	03/01/2026		F		15,585(3)	D	$31.26	101,875	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The Reporting Person acquired these shares pursuant to a Restricted Stock Award under the AtriCure, Inc. 2023 Stock Incentive Plan. One third of the shares will vest annually upon the respective one, two, and three year anniversaries of the date of grant.

2. The Reporting Person acquired these shares pursuant to the vesting and release of a Performance Share Award under the AtriCure, Inc. 2023 Stock Incentive Plan. The award had Company performance goals and a service period requirement which were met.

3. The Reporting Person has elected to transfer these shares to the Company to satisfy the tax withholding obligation incurred upon the vesting and release of shares previously acquired pursuant to a Restricted Stock Award or Performance Share Award.

Remarks:

	/s/ Vinayak S. Doraiswamy	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did AtriCure (ATRC) report for its Chief Scientific Officer?

AtriCure’s Chief Scientific Officer Doraiswamy Vinayak reported equity grants and a tax-related share transfer. He received restricted stock and performance-based shares, then transferred other shares back to the company to satisfy tax withholding obligations tied to prior award vesting.

How many AtriCure (ATRC) shares were granted to the Chief Scientific Officer?

Doraiswamy Vinayak was granted 30,390 AtriCure common shares as a restricted stock award and 15,198 shares from a performance share award. Both awards were made under the AtriCure, Inc. 2023 Stock Incentive Plan, subject to vesting and performance conditions.

What are the vesting terms of the new restricted stock award at AtriCure (ATRC)?

The new restricted stock award for AtriCure’s Chief Scientific Officer vests in three equal installments. One third of the 30,390 granted shares will vest on each of the first, second, and third anniversaries of the March 1 grant date, assuming continued eligibility.

What conditions applied to the AtriCure (ATRC) performance share award that vested?

The performance share award that delivered 15,198 AtriCure shares had company performance goals and a service period requirement. According to the disclosure, both the performance conditions and service requirement were met, triggering the vesting and release of those shares to the executive.

Why did AtriCure’s Chief Scientific Officer transfer shares back to the company?

Doraiswamy Vinayak transferred 15,585 AtriCure shares back to the company to cover tax withholding obligations. These obligations arose from the vesting and release of shares previously received through restricted stock or performance share awards, at a reported price of $31.26 per share.

Were the AtriCure (ATRC) insider share transfers open-market sales?

The filing characterizes the 15,585-share disposition as satisfying tax withholding obligations by delivering shares to the company. This is described as a tax-related transfer rather than an open-market sale, tied to earlier equity award vesting and release events.